0000000000514259

AUTHOR

Aldo Scarpa

showing 33 related works from this author

Malignant epithelial/exocrine tumors of the pancreas

2020

Summary Pancreatic malignant exocrine tumors represent the most important cause of cancer-related death for pancreatic neoplasms. The most common tumor type in this category is represented by pancreatic ductal adenocarcinoma (PDAC), an ill defined, stroma-rich, scirrhous neoplasm with glandular differentiation. Here we present the relevant characteristics of the most important PDAC variants, namely adenosquamous carcinoma, colloid carcinoma, undifferentiated carcinoma, undifferentiated carcinoma with osteoclast-like giant cells, signet ring carcinoma, medullary carcinoma and hepatoid carcinoma. The other categories of malignant exocrine tumors, characterized by fleshy, stroma-poor, circumsc…

acinarPathologymedicine.medical_specialtyAdenosquamous carcinomapancreatic cancerPancreatoblastomapancreatic ductal adenocarcinomaReviewAdenocarcinomaGlandular DifferentiationPathology and Forensic MedicinePancreatic cancersolid pseudopapillary.medicineCarcinomaNeoplasmHumansacinar; pancreatic cancer; pancreatic ductal adenocarcinoma; PDAC; solid pseudopapillaryPancreasbusiness.industryPDACPDAC; acinar; pancreatic cancer; pancreatic ductal adenocarcinoma; solid pseudopapillarymedicine.diseasePancreas ExocrinePancreatic Neoplasmssolid pseudopapillarymedicine.anatomical_structureMedullary carcinomaPancreasbusinessCarcinoma Pancreatic Ductal
researchProduct

Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to …

2019

This study aims at clarifying the prognostic role of high-grade tumor budding (TB) in pancreatic ductal adenocarcinoma (PDAC) with the first systematic review and meta-analysis on this topic. Furthermore, we analyzed with a systematic review the relationship between TB and a recently suggested TB-associated mechanism: the epithelial to mesenchymal transition (EMT). Analyzing a total of 613 patients, 251 of them (40.9%) with high grade-TB, we found an increased risk of all-cause mortality (RR, 1.46; 95% CI, 1.13-1.88, p = 0.004; HR, 2.65; 95% CI, 1.79-3.91; p < 0.0001) and of recurrence (RR, 1.61; 95% CI, 1.05-2.47, p = 0.03) for PDAC patients with high-grade TB. Moreover, we found that E…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPancreatic ductal adenocarcinomapancreatic cancerHigh grade tumorReviewEMT; budding; buds; epithelial to mesenchymal transition; pancreatic cancerbuddinglcsh:RC254-28203 medical and health sciences0302 clinical medicineTumor buddingPancreatic cancerInternal medicineMedicineClinical significanceEpithelial–mesenchymal transitionbusiness.industryEMTepithelial to mesenchymal transitionbudslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasebud3. Good health030104 developmental biologyIncreased riskOncology030220 oncology & carcinogenesisMeta-analysisbusinessCancers
researchProduct

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option

2017

Abstract: Biliary tract cancers (BTCs) are characterized by a bad prognosis and the armamentarium of drugs for their treatment is very poor. Although the inflammatory status of biliary tract represents the first step in the cancerogenesis, the microenvironment also plays a key role in the pathogenesis of BTCs, promoting tumor angiogenesis, invasion and metastasis. Several molecules, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), are involved in the angiogenesis process and their expression on tumor samples has been explored as prognostic marker in both cholangiocarcinoma and gallbladder cancer. Recent studies evaluated the genomic landscape of BTCs and…

0301 basic medicineMAPK/ERK pathwayVascular Endothelial Growth Factor AAngiogenesisDrug Evaluation PreclinicalTyrosine kinase inhibitorAngiogenesis InhibitorsReviewFibroblast growth factorCatalysiMetastasisAntineoplastic Agentlcsh:Chemistrychemistry.chemical_compoundangiogenesis0302 clinical medicinetyrosine kinase inhibitorsMolecular Targeted Therapylcsh:QH301-705.5SpectroscopyClinical Trials as TopicMonoclonal antibodieNeovascularization Pathologicvascular endothelial growth factorComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineComputer Science ApplicationsVascular endothelial growth factorGene Expression Regulation NeoplasticAngiogenesiChemistryBiliary Tract NeoplasmsTreatment OutcomeBiliary Tract Neoplasm030220 oncology & carcinogenesismonoclonal antibodiesTyrosine kinaseAngiogenesis InhibitorHumanSignal TransductionProtein Kinase InhibitorAntineoplastic Agentsbiliary tract cancersBiologyModels BiologicalAngiogenesis; Biliary tract cancers; Monoclonal antibodies; Tyrosine kinase inhibitors; Vascular endothelial growth factor; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biliary Tract Neoplasms; Clinical Trials as Topic; Drug Evaluation Preclinical; Gene Expression Regulation Neoplastic; Genetic Variation; Humans; Models Biological; Neovascularization Pathologic; Protein Kinase Inhibitors; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A; Molecular Targeted Therapy; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic ChemistryCatalysisInorganic Chemistry03 medical and health sciencesIn vivomedicineAnimalsHumansPhysical and Theoretical ChemistryGallbladder cancerMolecular BiologyProtein Kinase InhibitorsBiologyAnimalOrganic ChemistryGenetic Variationmedicine.disease030104 developmental biologychemistrylcsh:Biology (General)lcsh:QD1-999Immunologyangiogenesis; biliary tract cancers; monoclonal antibodies; tyrosine kinase inhibitors; vascular endothelial growth factorCancer researchBiliary tract cancerInternational Journal of Molecular Sciences
researchProduct

Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets?

2015

Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and few chemotherapeutic choices. MicroRNAs (miRNAs) are non-coding, single-stranded RNAs of around 22 nucleotides involved in the pathogenic mechanisms of carcinogenesis and metastasis. They have been studied in many tumors in order to identify potential diagnostic, prognostic or therapeutic targets. In the current literature, many studies have analyzed the role of miRNAs in PDAC. In fact, the absence of appropriate biomarkers, the difficultly of early detection of this tumor, and the lack of effective chemotherapy in patients with unresectable disease have focused attention on miRNAs as new, i…

Maleendocrine system diseasesPrognosiSettore MED/06 - Oncologia MedicaMice NudeReviewDiseaseAdenocarcinomaMalignancymedicine.disease_causeMetastasisMicemicroRNABiomarkers TumorCarcinomamedicineAnimalsHumansmiRNAbiomarkers; miRNAs; pancreatic adenocarcinoma; prognosis; therapyAnimalbusiness.industryPancreatic NeoplasmbiomarkersMicroRNABiomarkerPrognosismedicine.diseasePhenotypedigestive system diseasesPancreatic NeoplasmsGene Expression Regulation NeoplasticMicroRNAsPhenotypeBiomarkers; miRNAs; Pancreatic adenocarcinoma; Prognosis; Therapy; Adenocarcinoma; Animals; Biomarkers Tumor; Carcinoma Pancreatic Ductal; Female; Gene Expression Regulation Neoplastic; Humans; Male; Mice; Mice Nude; MicroRNAs; Pancreatic Neoplasms; Phenotype; Prognosis; OncologyOncologymiRNAsImmunologyCancer researchAdenocarcinomaFemaleTherapybusinessCarcinogenesisPancreatic adenocarcinomaCarcinoma Pancreatic DuctalHuman
researchProduct

Extranodal extension in N1-adenocarcinoma of the pancreas and papilla of Vater: A systematic review and meta-analysis of its prognostic significance

2016

The aim of the study was to investigate the prognostic role of extranodal extension (ENE) of lymph node metastasis in adenocarcinoma of the pancreas (PDAC) and papilla [cancer of the papilla of Vater (CPV)]. A PubMed and SCOPUS search from database inception until 5 January 2015 without language restrictions was conducted. Eligible were prospective studies reporting data on prognostic parameters in individuals with PDAC and/or CPV, comparing participants with the presence of ENE (ENE +) with those with intranodal extension (ENE). Data were summarized using risk ratios for number of deaths/recurrences and hazard ratios for time-dependent risk related to ENE+, adjusted for potential confounde…

Time FactorsPapillaPapillary carcinomaGastroenterologyextranodal extension pancreatic adenocarcinoma papilla papillary carcinoma prognosislymph node metastasis adenocarcinoma of the pancreas (PDAC) papilla [cancer of the papilla of Vater (CPV)] extranodal extension (ENE)0302 clinical medicineRisk FactorsOdds RatioProspective cohort studylymph node metastasisHazard ratioAmpulla of VaterGastroenterologyPrognosisextranodal extension (ENE)medicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisLymphatic Metastasisadenocarcinoma of the pancreas (PDAC)Disease ProgressionAdenocarcinoma030211 gastroenterology & hepatologymedicine.medical_specialtyAmpulla of VaterCommon Bile Duct NeoplasmsAdenocarcinomapapilla [cancer of the papilla of Vater (CPV)]Disease-Free Survival03 medical and health sciencesExtranodal extension; Pancreatic adenocarcinoma; Papilla; Papillary carcinoma; Prognosis; Gastroenterology; HepatologyPredictive Value of TestsInternal medicineExtranodal extensionmedicineHumansHepatologybusiness.industryOdds ratiomedicine.diseaseConfidence intervalSurgeryMajor duodenal papillaPancreatic NeoplasmsRelative riskLymph NodesNeoplasm Recurrence LocalbusinessPancreatic adenocarcinoma
researchProduct

Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?

2021

Gastroenteropancreatic neuroendocrine neoplasia (GEPNEN) comprises clinically as well as prognostically diverse tumour entities often diagnosed at late stage. Current classification provides a uniform terminology and a Ki67-based grading system, thereby facilitating management. Advances in the study of genomic and epigenetic landscapes have amplified knowledge of tumour biology and enhanced identification of prognostic and potentially predictive treatment subgroups. Translation of this genomic and mechanistic biology into advanced GEPNEN management is limited. ‘Targeted’ treatments such as somatostatin analogues, peptide receptor radiotherapy, tyrosine kinase inhibitors and mammalian target…

0301 basic medicinemedicine.medical_treatmentcancer geneticsNeuroendocrine tumorsBioinformaticschemotherapyMolecular oncologyEpigenesis Genetic03 medical and health sciences0302 clinical medicinemolecular oncologyStomach NeoplasmsIntestinal NeoplasmsBiomarkers TumormedicineHumanscancer genetics; chemotherapy; immunotherapy; molecular oncology; neuroendocrine tumorsEpigeneticsPrecision Medicine610 Medicine & healthbusiness.industryGastroenterologyImmunotherapymedicine.diseasePancreatic NeoplasmsRadiation therapyClinical trial030104 developmental biologyTargeted drug delivery030220 oncology & carcinogenesis570 Life sciences; biologyIdentification (biology)immunotherapyneuroendocrine tumorsbusiness
researchProduct

Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma

2018

Strong prognostic markers able to stratify lung adenocarcinoma (ADC) patients are lacking. We evaluated whether a six-immunohistochemical markers panel (TTF1, SP-A, Napsin A, MUC5AC, CDX2 and CK5), defining the putative neoplastic “cell of origin,” allows to identify prognostic subgroups among lung ADC. We screened a large cohort of ADC specimens (2003–2013) from Torino Institutional Repository identifying: (i) marker positivity by immunohistochemistry, (ii) main morphological appearance by light microscopy, (iii) presence of “hotspot” mutations of candidate genes by Sequenom technology. To evaluate possible predictors of survival and time to recurrence, uni- and multivariable-adjusted comp…

Lung adenocarcinomaMorphologyAdultMale0301 basic medicineOncologyBiomarkers; Genetic mutations; Immunohistochemistry; Lung adenocarcinoma; Morphology; Survival analysisPathologymedicine.medical_specialtyCandidate geneCell of originsix-immunohistochemical markers panel (TTF1 SP-A Napsin A MUC5AC CDX2 and CK5)Adenocarcinoma of LungKaplan-Meier Estimategenetic mutationsGene mutationBiologymedicine.disease_causeadenocarcinoma (ADC)survival analysisPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineInternal medicinemorphologyBiomarkers TumormedicineHumansCDX2Survival analysisAgedbiomarkers; genetic mutations; immunohistochemistry; lung adenocarcinoma; morphology; survival analysisbiomarkersSurvival analysisMiddle Agedrespiratory systemPrognosislung adenocarcinomamedicine.diseaseImmunohistochemistryGenetic mutations030104 developmental biology030220 oncology & carcinogenesisimmunohistochemistryAdenocarcinomaImmunohistochemistryFemaleKRASBiomarkersHuman Pathology
researchProduct

Intraductal tubulopapillary neoplasm (ITPN) of the pancreas: a distinct entity among pancreatic tumors

2022

Aims Intraductal tubulopapillary neoplasm (ITPN) of the pancreas is a recently recognized pancreatic tumor entity. Here we aimed to determine the most important features with a systematic review coupled with an integrated statistical approach. Methods and results PubMed, SCOPUS, and Embase were searched for studies reporting data on pancreatic ITPN. The clinicopathological, immunohistochemical, and molecular data were summarized. Then a comprehensive survival analysis and a comparative analysis of the molecular alterations of ITPN with those of pancreatic ductal adenocarcinoma (PDAC) and intraductal papillary mucinous neoplasm (IPMN) from reference cohorts (including the International Cance…

HistologyIPMNITPNPancreatic Intraductal NeoplasmsPDACpancreatic ductal adenocarcinomaGeneral MedicineCarcinoma PapillaryPathology and Forensic MedicinePancreatic Neoplasmspancreatubulopapillary.TubulopapillaryHumansintraductalPrecision MedicineIPMN; ITPN; Intraductal; PDAC; Tubulopapillary; pancreas; pancreatic ductal adenocarcinomaPancreasCarcinoma Pancreatic Ductal
researchProduct

TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC)

2012

ABSTRACT Background TH-302 is a hypoxia targeted prodrug with a hypoxia-triggered 2-nitroimidazole component designed to release the DNA alkylator, bromo-isophosphoramide mustard (Br-IPM), when reduced in severe hypoxia. A randomized Phase 2B study (NCT01144455) was conducted to assess the benefit of G + T to standard dose G as first-line therapy of PAC. Materials and methods An open-label multi-center study of two dose levels of TH-302 (240 mg/m2 or 340 mg/m2) in combination with G versus G alone (randomized 1:1:1). G (1000 mg/m2) and T were administered IV over 30-60 minutes on Days 1, 8 and 15 of a 28-day cycle. Patients on the G could crossover after progression and be randomized to a G…

medicine.medical_specialtyGastrointestinal tumorsPerformance statusbusiness.industryHematologySevere hypoxiaNeutropeniamedicine.diseaseRashGastroenterologyDiscontinuationNon colorectalOncologyInternal medicineToxicitymedicinemedicine.symptombusinessAnnals of Oncology
researchProduct

Prognostic implications of extranodal extension in node-positive squamous cell carcinoma of the vulva: A systematic review and meta-analysis

2016

Squamous cell carcinoma (SCC) of the vulva is the fourth most common gynecological cancer, usually staged with the TNM or FIGO systems. Since 2009, FIGO staging has taken the extranodal extension (ENE) of lymph node metastases into account. ENE is defined as the spread of a lymph node metastasis into surrounding soft tissue. Although the TNM and FIGO systems acknowledge the importance of ENE in SCC, no comprehensive studies have analyzed the prognostic impact of this parameter. We therefore queried the PubMed and SCOPUS databases from their inception up until 04/01/2015, adopting no language restrictions: all prospective studies reporting on prognostic parameters in patients with vulvar SCC…

Oncologymedicine.medical_specialtyExtranodal metastasisVulva03 medical and health sciences0302 clinical medicineInternal medicineExtranodal extensionmedicineHumans030212 general & internal medicineProspective cohort studyLymph nodeGynecologyVulvar neoplasmVulvar NeoplasmsVulvar cancerbusiness.industryENE; Extranodal extension; Extranodal metastasis; Vulvar cancer; Oncology; SurgeryHazard ratioVulvar cancerENE; Extranodal extension; Extranodal metastasis; Vulvar cancermedicine.diseasePrognosisExtranodal metastasimedicine.anatomical_structureOncology030220 oncology & carcinogenesisMeta-analysisRelative riskCarcinoma Squamous CellENEFemaleSurgeryLymph Nodesbusiness
researchProduct

Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas

2022

Undifferentiated sarcomatoid carcinoma (USC) of the pancreas is a rare but especially aggressive variant of pancreatic ductal adenocarcinoma (PDAC), composed of at least 80% of sarcomatoid cells. This study aimed to elucidate its clinicopathological and molecular features. The study cohort included 10 patients with pancreatic USC. Clinicopathological parameters were determined for each patient. The molecular profile was investigated using next-generation sequencing (NGS). Histologically, all tumors were hypercellular neoplasms with spindle-shaped or sarcomatoid cells. All patients showed vascular and perineural invasion. Most patients had a poor prognosis. NGS showed important similarities …

GenomicsPancreatic cancerAdenocarcinomaKRAS; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Sarcomatoid; UndifferentiatedSarcomatoidPathology and Forensic MedicineKRAS Pancreatic cancer Pancreatic ductal adenocarcinoma Sarcomatoid UndifferentiatedPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Pancreatic ductal adenocarcinomaMutationUndifferentiatedKRASHumansMyeloid Cell Leukemia Sequence 1 ProteinPancreasCarcinoma Pancreatic Ductal
researchProduct

Inflammatory and tumor-like lesions of the pancreas

2020

Summary Inflammatory/tumor-like lesions of the pancreas represent a heterogeneous group of diseases that can variably involve the pancreatic gland determining different signs and symptoms. In the category of inflammatory/tumor-like lesions of the pancreas, the most important entities are represented by chronic pancreatitis, which includes alcoholic, obstructive and hereditary pancreatitis, paraduodenal (groove) pancreatitis, autoimmune pancreatitis, lymphoepithelial cyst, pancreatic hamartoma and intrapancreatic accessory spleen. An in-depth knowledge of such diseases is essential, since they can cause severe morbidity and may represent a potential life-threatening risk for patients. Furthe…

Pathologymedicine.medical_specialtyautoimmune pancreatitiReviewSettore MED/08 - Anatomia PatologicaAccessory spleenparaduodenal pancreatitisPathology and Forensic MedicineDiagnosis Differentialchronic pancreatitisPancreatitis Chronicparaduodenal pancreatitis.groovemedicineHamartomaPancreasAutoimmune pancreatitisHereditary pancreatitisbusiness.industrymedicine.diseaseautoimmune pancreatitisPancreatic Neoplasmspancreatic pathologymedicine.anatomical_structurePancreatitisSevere morbidityPancreatitischronic pancreatitiDifferential diagnosisPancreasbusinessautoimmune pancreatitis; chronic pancreatitis; groove; pancreatic pathology; paraduodenal pancreatitis
researchProduct

Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis

2018

Extranodal extension (ENE) of nodal metastasis is defined as the extension of metastatic cells through the nodal capsule into the perinodal tissue. This morphological parameter, recently proposed as an important prognostic factor in different types of malignancy, has not been included in the TNM staging system for non-small cell lung cancer (NSCLC). In this systematic review with meta-analysis, we weighted the prognostic role of ENE in patients with lymph node-positive NSCLC. Two independent authors searched SCOPUS and PubMed through 28 February 2017. Prospective and retrospective studies on NSCLC, comparing patients with presence of ENE (ENE+) ENE+) vs. only intranodal extension (ENE–) and…

Oncologymedicine.medical_specialtyLung NeoplasmsExtracapsular; Extranodal; Lung cancer; Metastasis; NSCLC; PrognosisTNM staging systemNSCLCMalignancyMetastasisPathology and Forensic MedicineMetastasis03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungInternal medicinemedicine030212 general & internal medicineLung cancerMolecular BiologyEne reactionLung cancer . NSCLC . Prognosis . Extranodal . Extracapsular . MetastasisExtracapsularbusiness.industryHazard ratioRetrospective cohort studyCell BiologyGeneral MedicinePrognosismedicine.diseaseLymphatic Metastasis030220 oncology & carcinogenesisRelative riskExtranodalLymph NodesLung cancerNeoplasm Recurrence Localbusiness
researchProduct

Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis

2017

AbstractThe extranodal extension (ENE) of nodal metastasis involves the extension of neoplastic cells through the lymph node capsule into the perinodal adipose tissue. This morphological feature has recently been indicated as an important prognostic factor in various cancer types, but its role in prostate cancer is still unclear. We aimed to clarify it, performing the first meta-analysis on this issue, comparing prognostic parameters in surgically treated, node-positive prostate cancer patients with (ENE+) vs. without (ENE−) ENE. Data were summarized using risk ratios (RRs) for number of deaths/recurrences and hazard ratios (HRs), with 95% confidence intervals (CI), for the time-dependent r…

Male0301 basic medicineBiochemical recurrenceOncologymedicine.medical_specialtyPathologyScienceprostate cancer he extranodal extension (ENE) perinodal adipose tissuenot knownArticle03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineJournal ArticleOdds RatioHumansMedicineperinodal adipose tissueNeoplasms Adipose TissueAgedProportional Hazards ModelsMultidisciplinarybusiness.industryProportional hazards modelQHazard ratioRProstateProstatic NeoplasmsCancerOdds ratioMiddle Agedprostate cancerPrognosismedicine.disease3. Good health030104 developmental biologyLymphatic Metastasis030220 oncology & carcinogenesisRelative riskhe extranodal extension (ENE)MedicineProstate surgeryLymph NodesNeoplasm Recurrence LocalbusinessScientific Reports
researchProduct

Colorectal cancer with microsatellite instability: Right-sided location and signet ring cell histology are associated with nodal metastases, and extr…

2021

Colorectal cancer (CRC) with microsatellite instability (MSI) accounts for 15-18 % of all CRCs and represents the category with the best prognosis. This study aimed at determining any possible clinical/pathological features associated with a higher risk of nodal metastasization in MSI-CRC, and at defining any possible prognostic moderators in this setting. All surgically resected CRCs of the last 20 years (mono-institutional series) with a PCR-based diagnosis of MSI, with and without nodal metastasis, have been retrieved for histological review, which was performed following WHO guidelines. Furthermore, the most important prognostic moderators have been investigated with a survival analysis…

AdultMale0301 basic medicineOncologycongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPrognostic variableColonColorectal cancerDisease-Free SurvivalMetastasisPathology and Forensic MedicineMetastasis03 medical and health sciences0302 clinical medicineInternal medicinedMMRmedicinerectumHumansStage (cooking)neoplasmsMSISurvival analysisAgedColon; ENE; Extracapsular; MSI; Metastasis; dMMR; rectumExtranodal ExtensionExtracapsularSignet ring cellbusiness.industryColon; dMMR; ENE; Extracapsular; Metastasis; MSI; rectumMicrosatellite instabilityCell BiologyMiddle AgedPrognosismedicine.diseaseProgression-Free Survivaldigestive system diseases030104 developmental biology030220 oncology & carcinogenesisENEFemaleMicrosatellite InstabilityColorectal NeoplasmsNODALbusinessCarcinoma Signet Ring CellPathology - Research and Practice
researchProduct

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial …

2015

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population …

Malemedicine.medical_specialtyAcute coronary syndromePopulationLIXisenatide610 Medicine & healthHypoglycemiaPlacebop38 Mitogen-Activated Protein Kinases11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicinelaw.inventionSettore MED/13 - EndocrinologiaAcute Coronary Syndrome; Aged; Cardiovascular Diseases; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Peptides; Placebos; Protein Kinase Inhibitors; Research Design; p38 Mitogen-Activated Protein Kinases; Cardiology and Cardiovascular MedicinePlacebosLixisenatidechemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawGlucagon-Like Peptide 1Internal medicineJournal ArticlemedicineHumansComparative StudyMyocardial infarctionAcute Coronary SyndromeeducationProtein Kinase InhibitorsAgededucation.field_of_studybusiness.industryUnstable anginaResearch Support Non-U.S. Gov'tta3121Middle Agedmedicine.diseaseSurgeryMulticenter StudychemistryCardiovascular DiseasesResearch DesignRandomized Controlled TrialCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPeptides
researchProduct

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer

2017

AbstractCombined MAPK/PI3K pathway inhibition represents an attractive, albeit toxic, therapeutic strategy in oncology. Since PTEN lies at the intersection of these two pathways, we investigated whether PTEN status determines the functional response to combined pathway inhibition. PTEN (gene, mRNA, and protein) status was extensively characterized in a panel of cancer cell lines and combined MEK/mTOR inhibition displayed highly synergistic pharmacologic interactions almost exclusively in PTEN-loss models. Genetic manipulation of PTEN status confirmed a mechanistic role for PTEN in determining the functional outcome of combined pathway blockade. Proteomic analysis showed greater phosphoprote…

0301 basic medicineMAPK/ERK pathwayPTENRNA interferenceprotein Kinase inhibitorsRNA Small InterferinghumansPhosphoinositide-3 Kinase InhibitorsAnimals; cell line tumor; drug synergism; everolimus; female; humans; Janus Kinase 1; MAP Kinase Kinase Kinases; mice; neoplastic stem cells; PTEN phosphohydrolase; phosphatidylinositol 3-Kinases; protein Kinase inhibitors; proto-oncogene Proteins c-akt; Pyridones; Pyrimidinones; RNA Interference; RNA Small Interfering; STAT3 Transcription Factor; TOR Serine-Threonine KinasesMultidisciplinaryMAPK/PI3K pathway inhibitiononcology MAPK/PI3K pathway inhibitionTOR Serine-Threonine Kinasescell lineMAPK/PI3K inhibition oncology. inhibition. PTEN gene mRNA cancer cell lines MEK/mTORMAP Kinase Kinase KinasesfemaleoncologymTORRNA InterferenceSTAT3 Transcription FactortumormicePyridonesMice NudePyrimidinonesBiologyphosphatidylinositol 3-KinasesSmall InterferingArticle03 medical and health sciencesMediatorSettore MED/04 - PATOLOGIA GENERALECell Line TumormedicinePTENAnimalsPI3K/AKT/mTOR pathwaydrug synergismSettore MED/06 - ONCOLOGIA MEDICAneoplastic stem cellsRPTORCancerJanus Kinase 1medicine.diseaseeverolimusproto-oncogene Proteins c-aktBlockade030104 developmental biologyCancer researchbiology.proteinRNAPTEN phosphohydrolase
researchProduct

PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: A expression patterns and clinical implications

2018

Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), a variant of pancreatic ductal adenocarcinoma (PDAC), has a striking genetic similarity to PDAC but a significantly improved overall survival. We hypothesize that this difference could be due to the immune response to the tumor, and as such, we investigated the expression of PD-1, PD-L1, and CD163 in a series of UCOGC. To this aim, 27 pancreatic UCOGCs (11 pure and 16 PDAC-associated), 5 extrapancreatic tumors with osteoclast-like giant cells and 10 pancreatic anaplastic carcinomas were immunostained using antibodies against PD-1, PD-L1, and CD163. In pancreatic UCOGCs, PD-L1 was expressed in neoplastic cells of 17 (63%) o…

Male0301 basic medicineIndianaProgrammed Cell Death 1 ReceptorOsteoclast; PDAC; Pancreatic Cancer; Tumor-Associated Macrophages; UCOGCOsteoclastsGiant CellsB7-H1 Antigen0302 clinical medicineTumor-Associated MacrophagesTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]LymphocytesAged 80 and overbiologyTumor-associated macrophagesCell DifferentiationMiddle AgedOsteoclast; Pancreatic cancer; PDAC; Tumor-associated macrophages; UCOGC; 2734ImmunohistochemistryEuropePhenotypemedicine.anatomical_structure030220 oncology & carcinogenesisOsteoclastFemaleAntibodyCarcinoma Pancreatic DuctalAdult2734Antigens Differentiation MyelomonocyticReceptors Cell SurfaceUCOGCPathology and Forensic MedicinePancreatic Cancer03 medical and health sciencesImmune systemAll institutes and research themes of the Radboud University Medical CenterAntigens CDOsteoclastPD-L1Pancreatic cancerBiomarkers TumormedicineHumansHistiocyteAgedNeoplasm StagingPDACHistiocytesPancreatic cancermedicine.diseasePancreatic Neoplasms030104 developmental biologyGiant cellCancer researchbiology.proteinCD163
researchProduct

Prognostic impact and implications of extra-capsular lymph node involvement in colorectal cancer: a systematic review with meta-analysis.

2015

The extranodal extension (ENE) of nodal metastasis (i.e. the extension of tumor cells through the nodal capsule into the perinodal adipose tissue) has recently emerged as an important prognostic factor in different types of malignancies. However, the tumor-node-metastasis (TNM) staging system for colorectal cancer does not consider it as a prognostic parameter. Therefore, we conducted a systematic review and meta-analysis to determine the prognostic role of ENE in patients with lymph node-positive colorectal cancer.Two independent authors searched PubMed and SCOPUS until 7 January 2015 without language restrictions. Prospective studies reporting data on prognostic parameters in subjects wit…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancerExtra-capsular extensionColon cancer; ENE; Extra-capsular extension; Extra-nodal extension; Lymph node metastasis; Rectal cancer03 medical and health sciences0302 clinical medicinecolon cancer; extracapsular extension; extranodal extension; lymph node metastasis; rectal cancerInternal medicineHumansMedicineextracapsular extensionRectal cancerProspective cohort studyLymph nodeProportional Hazards ModelsLymph node metastasisbusiness.industryProportional hazards modelHazard ratioCancerextranodal extensionHematologyPrognosismedicine.diseaseColon cancerTreatment Outcome030104 developmental biologymedicine.anatomical_structureOncologyLymphatic Metastasis030220 oncology & carcinogenesisMeta-analysisENEextranodal extension extracapsular extension lymph node metastasis colon cancer rectal cancerRegression AnalysisT-stageExtra-nodal extensionLymph NodesNeoplasm Recurrence LocalColorectal Neoplasmsbusiness
researchProduct

Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: A systematic review and meta-analysis

2015

Loss of the tumor suppressor gene AT-rich interactive domain-containing protein 1A (ARID1A) has been demonstrated in several cancers, but its prognostic role is unknown. We aimed to investigate the risk associated with loss of ARID1A (ARID1A-) for all-cause mortality, cancer-specific mortality and recurrence of disease in subjects with cancer. PubMed and SCOPUS search from database inception until 01/31/2015 without language restriction was conducted, contacting authors for unpublished data. Eligible were prospective studies reporting data on prognostic parameters in subjects with cancer, comparing participants with presence of ARID1A (ARID1A+) vs. ARID1A-, assessed either via immunohistoch…

OncologyMalemedicine.medical_specialtyBioinformaticsARID1A SWI/SNF chromatin remodeling targeted therapy tumor suppressor genechromatin remodelingCohort StudiesARID1A; Chromatin remodeling; SWI/SNF; Targeted therapy; Tumor suppressor gene; OncologyInternal medicineNeoplasmsMedicineHumansARID1A; SWI/SNF; chromatin remodeling; targeted therapy; tumor suppressor geneGenes Tumor Suppressortumor suppressor geneProspective cohort studybusiness.industryConfoundingHazard ratioCancerNuclear ProteinsMiddle Agedmedicine.diseasePrognosistargeted therapyARID1AConfidence intervalDNA-Binding ProteinsSWI/SNFOncologyRelative riskMeta-analysisMutationFemalebusinessCohort studyResearch PaperTranscription Factors
researchProduct

Extra-nodal extension is an important prognostic parameter for both colonic and rectal cancer.

2016

0301 basic medicineOncologymedicine.medical_specialtyLymphatic metastasisColorectal cancerMEDLINE03 medical and health sciences0302 clinical medicineExtranodal extensionInternal medicinecolonic and rectal cancermedicineHumansRectal Neoplasmsbusiness.industryExtranodal ExtensionHematologyPrognosismedicine.disease030104 developmental biologyOncologyLymphatic Metastasis030220 oncology & carcinogenesisColonic NeoplasmsOncology; Hematologybusiness
researchProduct

Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring

2022

Ki-67 assessment is a key step in the diagnosis of neuroendocrine neoplasms (NENs) from all anatomic locations. Several challenges exist related to quantifying the Ki-67 proliferation index due to lack of method standardization and inter-reader variability. The application of digital pathology coupled with machine learning has been shown to be highly accurate and reproducible for the evaluation of Ki-67 in NENs. We systematically reviewed all published studies on the subject of Ki-67 assessment in pancreatic NENs (PanNENs) employing digital image analysis (DIA). The most common advantages of DIA were improvement in the standardization and reliability of Ki-67 evaluation, as well as its spee…

Reproducibility of ResultsBreast NeoplasmsCarcinoid TumorPathology and Forensic MedicinePancreatic Neoplasmsneuroendocrine neoplasms pancreasNeuroendocrine TumorsKi-67 AntigenGastroenteropancreatic Neuroendocrine TumorBiomarkers TumorImage Processing Computer-AssistedHumansGastroenteropancreatic Neuroendocrine Tumor; Cancer; Carcinoid TumorFemaleCell ProliferationCancer
researchProduct

Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma

2018

Objective Ampulla of Vater carcinoma (AVC) has a broad spectrum of different prognoses. As such, new moderators of survival are urgently needed. We aimed at clarifying the prognostic role of perineural invasion in AVC. Methods Using PubMed and SCOPUS databases, we conducted the first systematic review and meta-analysis on this topic. Results Analyzing 29 articles for a total of 2379 patients, we found that the presence of perineural invasion increased the risk of all-cause mortality more than 2 times (relative risk [RR], 2.07; 95% confidence interval [CI], 1.78-2.42 [P < 0.0001]; hazard ratio [HR], 2.72; 95% CI, 1.86-3.97 [P < 0.0001]), of cancer-specific mortality more than 6 times (…

Ampulla of Vatermedicine.medical_specialtyEndocrinology Diabetes and MetabolismPNIPerineural invasionPerineumGastroenterology03 medical and health sciencesBroad spectrum0302 clinical medicineEndocrinologypapilla PNI perineural VaterRisk FactorsInternal medicineInternal MedicinemedicineCarcinomaHumansNeoplasm InvasivenessVaterpapillaHepatologybusiness.industryHazard ratioAmpulla of VaterPrognosismedicine.diseaseConfidence intervalPancreatic Neoplasmsmedicine.anatomical_structure030220 oncology & carcinogenesisRelative riskMeta-analysisperineural030211 gastroenterology & hepatologyNeoplasm Recurrence LocalbusinessCarcinoma Pancreatic DuctalPancreas
researchProduct

Significance of the prognostic stratification of extranodal extension in colorectal cancer

2016

0301 basic medicineOncologymedicine.medical_specialtyLymphatic metastasisbusiness.industryColorectal cancerExtranodal Extensionextranodal extensioncolorectal cancerHematologymedicine.diseasePrognostic stratification03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineMedicinebusinessAnnals of Oncology
researchProduct

PBRM1 loss is a late event during the development of cholangiocarcinoma

2017

Aims: Somatic mutations in genes encoding chromatin remodellers have been reported recently in several cancer types, including approximately half of cholangiocarcinomas. One of the most commonly mutated chromatin remodellers in cholangiocarcinoma is the Polybromo-1 (PBRM1) gene located on chromosome 3p21, which encodes a subunit of the SWI/SNF complex. The aim of this study was to determine the timing of PBRM1 mutations in biliary carcinogenesis. Methods and results: In order to accomplish this goal, we used immunohistochemistry to assess PBRM1 protein expression in a series of precursor lesions and invasive biliary carcinomas. Previous studies have correlated loss of protein expression on …

0301 basic medicinePathologymedicine.medical_specialtyHistologyBilIN; PBRM1; biliary dysplasia; cholangiocarcinoma; chromatin remodellingchromatin remodellingKaplan-Meier EstimateBiologymedicine.disease_causeArticleBilIN; PBRM1; biliary dysplasia; cholangiocarcinoma; chromatin remodelingChromatin remodelingchromatin remodelingPathology and Forensic MedicinePBRM1PBRM103 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansBilinIntrahepatic CholangiocarcinomaProportional Hazards ModelsBilINMutationNuclear ProteinsCancerGeneral MedicinePrognosismedicine.diseaseChromatinDNA-Binding Proteinsbiliary dysplasiaCell Transformation Neoplastic030104 developmental biologyBile Duct Neoplasmschemistry030220 oncology & carcinogenesisMutationCarcinogenesischolangiocarcinomaTranscription Factors
researchProduct

An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated an…

2009

Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with a very poor 5-year survival rate. alpha-Enolase is a glycolytic enzyme that also acts as a surface plasminogen receptor. We find that it is overexpressed in PDAC and present on the cell surface of PDAC cell lines. The clinical correlation of its expression with tumor status has been reported for lung and hepatocellular carcinoma. We have previously demonstrated that sera from PDAC patients contain IgG autoantibodies to alpha-enolase. The present work was intended to assess the ability of alpha-enolase to induce antigen-specific T cell responses. We show that alpha-enolase-pulsed dendritic cells (DC) specifically stimulate healt…

KeratinocytesCancer ResearchPancreatic diseaseendocrine system diseasesalpha-enolaseAntibodies NeoplasmAlpha-enolaseT-LymphocytesMiceSkinImmunity Cellularhuman; pancreatic ductal adenocarcinoma; alpha enolase; tumor antigen; B cell response; T cell responsebiologyalpha enolasehuman; pancreatic ductal adenocarcinoma; alpha-enolase; tumor antigen; B cell response; T cell responseImmunohistochemistryTumor antigenUp-RegulationGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyAntibodyCarcinoma Pancreatic DuctalB cell responseT cellBlotting Westernpancreatic ductal adenocarcinomaGene Expression Regulation EnzymologicInterferon-gammaImmune systemAntigenAntigens NeoplasmCell Line TumorPancreatic cancermedicineAnimalsHumanshumanPancreasCell ProliferationDendritic Cellsmedicine.diseaseT cell responsepancreatic ductal adenocarcinoma; alpha-enolase; tumor antigen.digestive system diseasesPancreatic NeoplasmsImmunoglobulin GPhosphopyruvate HydrataseAntibody FormationImmunologybiology.proteintumor antigenT-Lymphocytes Cytotoxic
researchProduct

Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer: A meta-analysis towards precision medicine

2019

Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall accuracy. We finally assessed the concordance rate of all mutations detected by multi-genes panels. Fourteen eligible studies involving 369 patients wer…

0301 basic medicineOncologymedicine.medical_specialtyCancer ResearchConcordanceprecision medicinepancreatic cancerReviewlcsh:RC254-282Circulating tumor cells (CTC)03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancermedicineLiquid biopsycfDNALiquid biopsyReceiver operating characteristicliquid biopsybusiness.industryCfDNAPrecision medicinePancreatic cancerPrecision medicinemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthCancer treatment030104 developmental biologyOncologycirculating tumor cells (CTC)030220 oncology & carcinogenesisMeta-analysisDiagnostic odds ratiobusinesscfDNA; circulating tumor cells (CTC); liquid biopsy; pancreatic cancer; precision medicine
researchProduct

Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms

2021

High-grade Gastroenteropancreatic Neuroendocrine neoplasms (H-NENs) comprehend well-differentiated tumors (NET G3) and poorly differentiated carcinomas (NEC) with proliferative activity indexes as mitotic count (MC) &gt

Oncologymedicine.medical_specialtyMyeloidmyeloid markersT cellCD3gastroenteropancreatic neuroendocrine neoplasms; myeloid markers; tumor microenvironmentCD33PopulationHuman leukocyte antigenSettore MED/08 - Anatomia PatologicaArticleSurgical pathology03 medical and health sciences0302 clinical medicineInternal medicinemedicinetumor microenvironmenteducation030304 developmental biologymyeloid marker0303 health sciencesTumor microenvironmenteducation.field_of_studybiologybusiness.industryRGeneral Medicinegastroenteropancreatic neuroendocrine neoplasms myeloid markers tumor microenvironmentgastroenteropancreatic neuroendocrine neoplasmsstomatognathic diseasesmedicine.anatomical_structure030220 oncology & carcinogenesisgastroenteropancreatic neuroendocrine neoplasmbiology.proteinMedicinebusiness
researchProduct

Extranodal extension of lymph node metastasis is a marker of poor prognosis in oesophageal cancer: A systematic review with meta-analysis

2016

The extranodal extension (ENE) of nodal metastasis is the extension of neoplastic cells through the nodal capsule into the perinodal adipose tissue. This histological feature has recently been indicated as an important prognostic factor in different types of malignancies; in this manuscript, we aim at defining its role in the prognosis of oesophageal cancer with the tool of meta-analysis. Two independent authors searched SCOPUS and PubMed until 31 August 2015 without language restrictions. The studies with available data about prognostic parameters in subjects with oesophageal cancer, comparing patients with the presence of ENE (ENE+) versus only intranodal extension (ENE-), were considered…

Poor prognosismedicine.medical_specialty2734OESOPHAGUSLymph node metastasisGastroenterologyCANCER; METASTASIS; OESOPHAGUS; 2734Pathology and Forensic MedicineMetastasis03 medical and health sciences0302 clinical medicineExtranodal extensionInternal medicinemedicinebusiness.industryExtranodal ExtensionConfoundingCancerCANCER; METASTASIS; OESOPHAGUSGeneral Medicinemedicine.diseaseCANCERSurgery030220 oncology & carcinogenesisMeta-analysisRelative riskMETASTASIS030211 gastroenterology & hepatologybusiness
researchProduct

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Itali…

2022

Constitutional BRCA1/BRCA2 pathogenic or likely pathogenic variants (PVs) are associated with an increased risk for developing breast and ovarian cancers. Current evidence indicates that BRCA1/2 PVs are also associated with pancreatic cancer, and that BRCA2 PVs are associated with prostate cancer risk. The identification of carriers of constitutional PVs in the BRCA1/2 genes allows the implementation of individual and family prevention pathways, through validated screening programs and risk-reducing strategies. According to the relevant and increasing therapeutic predictive implications, the inclusion of BRCA testing in the routine management of patients with breast, ovarian, pancreatic and…

Societies ScientificMaleOvarian NeoplasmsCancer Researchgenetic counselingBRCABRCA testing; BRCA-related cancer; BRCA1; BRCA2; PARP inhibitors; genetic counseling; pancreatic ductal adenocarcinomaProstatic Neoplasmspancreatic ductal adenocarcinomaScientificSettore MED/03 - GENETICA MEDICABRCA testing; BRCA-related cancer; BRCA1; BRCA2; PARP inhibitors; genetic counseling; pancreatic ductal adenocarcinoma; Female; Humans; Italy; Male; Societies Scientific; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic NeoplasmsBRCA1BRCA2BRCA-related cancerPancreatic NeoplasmsBRCA testingPARP inhibitorOncologyItalyHumansFemaleSocietiesPARP inhibitors
researchProduct

Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysis

2016

Biallelic inactivation of the tumor suppressor gene BRCA1-associated protein 1 (BAP1) has been demonstrated in several cancers, but its prognostic role has not been completely explained. We aimed to investigate the risk associated with loss of BAP1 (BAP1-) for all-cause mortality, cancer-specific mortality and recurrence of disease in subjects with cancer. PubMed and SCOPUS were searched from database inception until 09/15/2015 without language restrictions. Prospective studies reporting data on prognostic parameters in subjects with cancer, comparing participants with presence of BAP1 (BAP1+) vs. BAP1- were included. Data were summarized using risk ratios (RR) for number of deaths/recurren…

MalePubMedTumor Suppressor ProteinsPrognosisGene BAP1not availableRisk FactorsNeoplasmsMutationprognosis in cancerHumansGene BAP1 prognosis in cancerFemaleGenes Tumor SuppressorNeoplasm Recurrence LocalUbiquitin Thiolesterase
researchProduct

Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes

2019

International audience; Previously, we classified colorectal cancers (CRCs) into five CRCAssigner (CRCA) subtypes with different prognoses and potential treatment responses, later consolidated into four consensus molecular subtypes (CMS). Here we demonstrate the analytical development and validation of a custom NanoString nCounter platform-based biomarker assay (NanoCRCA) to stratify CRCs into subtypes. To reduce costs, we switched from the standard nCounter protocol to a custom modified protocol. The assay included a reduced 38-gene panel that was selected using an in-house machine-learning pipeline. We applied NanoCRCA to 413 samples from 355 CRC patients. From the fresh frozen samples (n…

Gene Expression ProfilingTumour heterogeneityCOLON-CANCERlcsh:Rlcsh:Medicine[SDV.CAN]Life Sciences [q-bio]/CancerColorectal cancerCLASSIFICATIONArticleTumour biomarkersData processing[SDV.CAN] Life Sciences [q-bio]/CancerTissue Array AnalysisGENE-EXPRESSION; COLON-CANCER; CLASSIFICATIONBiomarkers TumorHumanslcsh:QColorectal Neoplasmslcsh:ScienceGENE-EXPRESSIONOligonucleotide Array Sequence Analysis
researchProduct

Pancreatic undifferentiated carcinoma with osteoclast-like giant cells is genetically similar to, but clinically distinct from, conventional ductal a…

2017

Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells (UCOGC) is currently considered a morphologically and clinically distinct variant of pancreatic ductal adenocarcinoma (PDAC). In this study, we report clinical and pathological features of a series of 22 UCOGCs, including the whole exome sequencing of eight UCOGCs. We observed that 60% of the UCOGCs contained a well-defined epithelial component and that patients with pure UCOGC had a significantly better prognosis than did those with an UCOGC with an associated epithelial neoplasm. The genetic alterations in UCOGC are strikingly similar to those known to drive conventional PDAC, including activating mutations in the…

PDAC variants; Undifferentiated carcinoma with osteoclast-like giant cells; whole exome sequencingAged 80 and overMaleendocrine system diseasesCarcinomaUndifferentiated carcinoma with osteoclast-like giant cellsundifferentiated carcinoma with osteoclast-like giant cellOsteoclastsMiddle AgedImmunohistochemistrydigestive system diseasesArticleNeoplasm Proteinswhole exome sequencingPDAC variants; undifferentiated carcinoma with osteoclast-like giant cells; whole exome sequencing; Aged; Aged 80 and over; Carcinoma Pancreatic Ductal; Exome; Female; Humans; Immunohistochemistry; Male; Middle Aged; Mutation; Neoplasm Proteins; Osteoclasts; Pancreatic NeoplasmsPancreatic NeoplasmsPDAC variantsPancreatic DuctalMutation80 and overHumansExomeFemaleAgedCarcinoma Pancreatic Ductal
researchProduct